Select Your Location:
Global
France
Italy

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies

Disease State: B-cell malignancies

Clemens Wendtner, Jennifer R. Brown, Loïc Ysebaert

Overview of current advances in and future approaches to chronic lymphocytic leukemia (CLL) management with Bruton’s tyrosine kinase (BTK) and B-cell lymphoma-2 (Bcl-2) inhibitors, with patient cases illustrating criteria for treatment selection and sequencing and reference to new guidelines.

Video
26 May 2025
Alessandra Tedeschi, Giorgio Minotti, Joe-Elie Salem, Stephan Stilgenbauer

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video
26 May 2025
Clemens Wendtner, Renata Walewska, Pier Luigi Zinzani, Matthew Davids

Overview of the treatment options for treatment naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and the use of BTKis in indolent lymphomas presented at the EHA2024 Hybrid Congress.

Video
26 May 2025